Reston, VA (August 1, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
New Imaging Tool Targets Hidden Liver Tumors
Liver cancer is hard to monitor after treatment, but a new PET imaging agent may help. Scientists developed a radiotracer that targets CD24, a protein found on liver tumor cells. In lab tests, the tracer accurately detected CD24-positive tumors in mice, offering a potential breakthrough in liver cancer imaging.
Tumor Response Patterns Offer Clues to Prostate Cancer Outcomes
Researchers used PSMA PET/CT scans to track prostate cancer spread in patients receiving therapy. They found that tumors responding differently within the same patient—called interlesional progression—predicted shorter survival. This imaging approach may help identify patients less likely to benefit from treatment early in their care journey.
Imaging Heart Health in Friedreich Ataxia
Friedreich ataxia affects the heart and nervous system, but tracking its progression is challenging. Researchers tested a PET method using a compound that detects mitochondrial activity. In both mice and humans, heart scans revealed reduced activity linked to the disease, offering a promising way to monitor treatment and progression.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
